WO2008055092A2 - Use of enoxaparin sodium for treating patients with acute ischemic stroke - Google Patents

Use of enoxaparin sodium for treating patients with acute ischemic stroke Download PDF

Info

Publication number
WO2008055092A2
WO2008055092A2 PCT/US2007/082788 US2007082788W WO2008055092A2 WO 2008055092 A2 WO2008055092 A2 WO 2008055092A2 US 2007082788 W US2007082788 W US 2007082788W WO 2008055092 A2 WO2008055092 A2 WO 2008055092A2
Authority
WO
WIPO (PCT)
Prior art keywords
enoxaparin sodium
administered
patient
enoxaparin
dosing period
Prior art date
Application number
PCT/US2007/082788
Other languages
French (fr)
Other versions
WO2008055092A3 (en
Inventor
Luis O. Toro-Figueroa
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008055092(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of WO2008055092A2 publication Critical patent/WO2008055092A2/en
Publication of WO2008055092A3 publication Critical patent/WO2008055092A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to methods for treating a human patient with acute ischemic stroke.
  • the methods comprise administering enoxaparin sodium (sometimes referred to herein as "enoxaparin”) to the human patient.
  • enoxaparin sometimes referred to herein as "enoxaparin”
  • the invention also relates to methods for preventing or treating thrombosis, such as thrombotic episodes or venous thromboses, in a human patient with acute ischemic stroke.
  • Enoxaparin sodium is available from sanofi-aventis under the trademark Lovenox® (Clexane® in some other countries).
  • Lovenox® Cosmetic® in some other countries.
  • Known enoxaparin sodium dosage regimens include those shown below:
  • a method for treating a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater comprising administering to said patient at least one dose of 40 mg of enoxaparin sodium for a therapeutic dosing period. Also provided is a method for preventing or treating thrombosis, such as thrombotic episodes, in a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater by treating that patient with enoxaparin.
  • enoxaparin sodium refers to the low molecular weight heparin (LMWH) approved by the U.S. Food and Drug Administration (FDA), or any other regulatory agency outside of the United States, as Lovenox ® (enoxaparin sodium injection), Clexane ® or Klexane ® , and any LMWH approved by the FDA, or any other regulatory agency outside of the United States, pursuant to an application citing Lovenox ® (enoxaparin sodium injection), Clexane ® or Klexane ® as the listed drug.
  • LMWH low molecular weight heparin
  • Enoxaparin sodium is available from sanofi-aventis and sold in the United States in the form of enoxaparin sodium injection, under the trademark Lovenox ® (Clexane ® in some other countries).
  • enoxaparin sodium is obtained by alkaline degradation of heparin benzyl ester derived from porcine intestinal mucosa. Its structure is characterized, for example, by a 2-0-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-0-disulfo-D-glucosamine at the reducing end of the chain.
  • the average molecular weight is about 4500 daltons.
  • the molecular weight distribution is:
  • Enoxaparin sodium injection is a sterile aqueous solution containing enoxaparin sodium.
  • Enoxaparin sodium injection is available from sanofi-aventis at 100 mg/ml in prefilled syringes (30 mg/0.3 mL pre-filled syringes, 40 mg/0.4 mL pre- filled syringes, 60 mg/0.6 mL pre-filled syringes, 80 mg/0.8 mL pre-filled syringes, and 100 mg/1.0 mL pre-filled syringes), graduated prefilled syringes, multiple-dose vials (300 mg/3.0 mL multi-dose vials), and ampoules (30 mg/0.3 mL).
  • Enoxaparin sodium injection 100 mg/mL concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL water for injection. Enoxaparin sodium injection is also available from sanofi-aventis at 150 mg/ml in graduated prefilled syringes (90 mg/0.6 mL pre-filled syringes, 120 mg/0.8 mL prefilled syringes, and 150 mg/1.0 mL pre-filled syringes).
  • Enoxaparin sodium injection 150 mg/mL concentration contains 15 mg enoxaparin sodium (approximate anti- Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 ml_ water for injection.
  • the enoxapahn sodium injection prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection.
  • the pH of the injection is 5.5 to 7.5.
  • Enoxaparin sodium injection may also be administered in an arterial line for a hemodialysis indication.
  • enoxaparin sodium once daily means, for example, administration every twenty-four hours plus or minus four hours.
  • prevent refers to the administration of therapy an individual who may ultimately manifest at least one symptom of a disease or condition (e.g., thrombosis) but who has not yet done so, to reduce the chance that the individual will develop the symptom of a disease or condition over a given period of time. Such a reduction may be reflected, for example, in a delayed onset of the at least one symptom of a disease or condition in the patient.
  • a disease or condition e.g., thrombosis
  • treat refers to the administration of therapy to an individual who already manifests at least one symptom of a disease or condition ⁇ e.g., thrombosis), or who has previously manifested at least one symptom of a disease or condition.
  • a disease or condition e.g., thrombosis
  • Body weight refers to the weight of a patient that is determined by actual weighing or by estimation prior to administration of enoxaparin sodium. In the event that the body weight of a patient is estimated prior to administration of the first dose of enoxaparin sodium, the body weight of the patient may be subsequently determined by actual weighing before any subsequent dose of enoxaparin, and the amount of enoxaparin administered to the patient with the next subsequent dose adjusted accordingly.
  • Kg body weight of the patient in kilograms.
  • stroke refers to the new onset of focal or global neurological deficit caused by ischemia or hemorrhage within or around the brain and lasting for more than 24 hours.
  • Intracranial hemorrhage may be diagnosed by appropriate brain imaging, including, for example, a CT or MRI that shows the presence of an acute blood mass.
  • Ischemic or bland infarction may be diagnosed, for example, by appropriate imaging which shows the presence of one or more of the following: hypodensity, edema, midline shift or ventricular effacement without evidence of hemorrhage.
  • Hemorrhagic conversion of an ischemic infarction may be diagnosed by appropriate imaging that shows an ischemic infarction with localized petechial or confluent bleeding into necrotic tissue.
  • acute ischemic stroke refers to strokes caused by thrombosis or embolism.
  • NIH Stroke Scale refers to National Institutes of Health Stroke Scale (NIHSS), used to measure the severity of neurological dysfunction at the time of a stroke.
  • the Stroke Scale typically is measured within 1 hour of an MRI or CT scan. A score greater than 25 indicates very severe neurological impairment; a score between 15 and 25 indicates severe impairment, while a score between 5 and 15 mild to moderately severe impairment, and a score less than 5 mild impairment.
  • therapeutic dosing period refers to the period of time beginning with the administration of a first dose of enoxapahn sodium and ending with the administration of the last dose of enoxaparin sodium on a continuing basis. For example, if enoxaparin sodium is administered approximately every twenty-four hours for a total of nine doses, the therapeutic dosing period is approximately 9 days (or approximately 216 hours), the time between the first dose and the ninth.
  • a method for treating a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater comprising administering to said patient at least one dose of 40 mg of enoxaparin sodium for a therapeutic dosing period. Also provided is a method for preventing or treating thrombosis, such as thrombotic episodes, in a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater by treating that patient with enoxaparin.
  • prevention of thrombosis comprises prevention of subsequent thrombotic episodes. In certain embodiments, prevention of thrombosis comprises prevention of venous thrombosis. In certain embodiments, treatment of thrombosis comprises treatment of thrombotic episodes. In certain embodiments, treatment of thrombosis comprises treatment of venous thrombosis.
  • enoxaparin sodium is, for example, by injection, and further for example, by subcutaneous injection.
  • the therapeutic dosing period is, for example, at least 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days. In certain embodiments, the therapeutic dosing period is about 10 days.
  • the dosage of enoxaparin sodium administered during the therapeutic dosing period is, for example, at least 20 mg, from more than 20 mg to less than 60 mg, from 22 mg to 58 mg, from 25 mg to 55 mg, from 27 mg to 52 mg, from 30 mg to 50 mg, from 32 mg to 47 mg, from 35 mg to 45 mg, from 37 mg to 43 mg, about 40 mg, or 40 mg.
  • about 40 mg (or 40 mg) of enoxaparin sodium is administered.
  • the enoxaparin sodium will be administered once daily.
  • the therapeutic dosing period is initiated with 48 hours of onset of stroke symptoms.
  • the patient undergoes a CT or MRI scan prior to administration of enoxaparin sodium to, e.g., confirm the diagnosis of acute ischemic stroke.
  • the patient is unable to walk without assistance due to motor impairment of one or both legs.
  • the motor impairment has lasted for at least 24 hours prior to administration of enoxaparin sodium.
  • the patient receiving enoxparin sodium typically will be 65 years of age or greater.
  • the patient is, for example, at least 70 years of age, at least 75 years of age, at least 80 years of age, at least 85 years of age, or at least 90 years of age.
  • the patient exhibits a NIH stroke score of, for example, at least 10, at least 11 , at least 12, at least 13, at least 14, or at least 15. In certain embodiments, the NIH stroke score is between about 5 and 15. In certain embodiments, the NIH stroke score is about 11.
  • enoxaparin is administered in an amount sufficient to reduce the primary end-point of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment, as compared with an ACT-adjusted UFH regimen.
  • DVT may be confirmed primarily by venography, or ultrasonography when venography was not practical.
  • PE may be confirmed by VQ scan, CT scan, or angiography.
  • administration of enoxapahn significantly reduced the incidence of the primary efficacy endpoint from by, for example, at least 30%, at least 35%, or at least 40%. In certain embodiments, the relative risk reduction was about 44%.
  • the patient is administered at least one additional therapeutic agent.
  • co-therapy may include the following examples: administration of each agent in a sequential manner in a regimen to provide beneficial effects of the drug combination; and/or co-administration of the aforementioned components in a substantially simultaneous manner (e.g., as in a single injection having a fixed ratio of these active agents or in multiple, separate injections for each agent, etc.).
  • the methods described herein are not limited in the sequence of administration; the enoxaparin sodium may be administered either prior to, at the same time with or after administration of the other agent.
  • enoxaparin sodium may be administered alone or in combination with other treatments, e.g., drug-eluting stent.
  • the at least one additional therapeutic agent is chosen from thrombolytic agents, fibrinolytic agents, neuroprotective agents, and antiplatelet agents.
  • the at least one additional therapeutic agent is a thrombolytic agent chosen from alteplase, anistreplase, reteplase, urokinase and streptokinase.
  • the at least one additional therapeutic agent is a neuroprotective agent chosen from caspase inhibitors, glutamate antagonists, calcium antagonists, opiate antagonists, GABA-A agonists, calpain inhibitors, NMDA receptor antagonists, K.sup. ⁇ channel modulators, PDH kinase inhibitors, and antioxidants.
  • the at least one additional therapeutic agent is an antiplatelet agent chosen from aspirin, clopidogrel, ticlopidine, abciximab, eptifibatide, tirofiban and dipyridamole.
  • the at least one additional therapeutic agent is a GP llb/llla inhibitor.
  • the GP llb/llla inhibitors include abciximab (marketed as ReoPro ® ), tirofiban (marketed as Aggrastat ® ), and eptifibatide (marketed as Integrelin ® ).
  • the at least one additional therapeutic agent is tissue plasminogen activator.
  • the at least one additional therapeutic agent is dipyridamole, such as extended release dipyridamole.
  • prevention of thrombosis comprises prevention of thrombotic episodes.
  • treatment of thrombosis comprises treatment of thrombotic episodes.
  • the dosage regimen for administration of enoxaparin sodium is based on the particular indication. For each indication, methods are provided herein that include methods for preventing and/or treating acute ischemic stroke in a human patient.
  • EXAMPLE 2 Treatment of a Stroke Patient
  • a patient who has suffered an acute ischemic stroke is identified.
  • the patient is 66 years old and the NIH stroke score of the patient is determined to be 11.3.
  • Enoxaparin is administered to the patient at a dose of 40 mg by subcutaneous injection once a day for ten days.
  • the patient does not suffer from any of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment.
  • the patient also does not suffer clinically significant intracranial bleeding or major extracranial bleeding during the ten days of treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for treating acute ischemic stroke in a patient in need thereof comprising administering an effective amount of enoxaparin sodium to the patient for a therapeutic dosing period are described. Also described are methods for preventing or treating thrombosis, such as thrombotic episodes, in a human patient with acute ischemic stroke by treating that patient with enoxaparin.

Description

ADMINISTRATION OF ENOXAPARIN SODIUM TO PATIENTS WITH ACUTE ISCHEMIC STROKE
[001] This invention relates to methods for treating a human patient with acute ischemic stroke. The methods comprise administering enoxaparin sodium (sometimes referred to herein as "enoxaparin") to the human patient. The invention also relates to methods for preventing or treating thrombosis, such as thrombotic episodes or venous thromboses, in a human patient with acute ischemic stroke.
[002] Enoxaparin sodium is available from sanofi-aventis under the trademark Lovenox® (Clexane® in some other countries). Known enoxaparin sodium dosage regimens include those shown below:
Dosage Regimen
Indication Standard Regimen Severe Renal Impairment
Prophylaxis in abdominal surgery 40 mg SC once daily 30 mg SC once daily
Prophylaxis in knee replacement 30 mg SC every 12 30 mg SC once daily surgery hours
Prophylaxis in hip replacement 30 mg SC every 12 30 mg SC once daily surgery hours or 40 mg SC once daily
Prophylaxis in medical patients 40 mg SC once daily 30 mg SC once daily
Inpatient treatment of acute DVT with 1 mg/kg SC every 1 mg/kg SC once or without pulmonary embolism 12 hours (with daily warfarin)
Outpatient treatment of acute DVT 1.5 mg/kg SC once 1 mg/kg SC once without pulmonary embolism daily (with warfarin) daily
Prophylaxis of ischemic 1 mg/kg SC every 1 mg/kg SC once daily complications of unstable angina and 12 hours (with non-Q-wave Ml aspirin)
Elderly: For treatment of acute Ml in elderly patients >=75 years of age, initiate dosing with 0.75 mg/kg SC every 12 hours
[003] Provided is a method for treating a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater comprising administering to said patient at least one dose of 40 mg of enoxaparin sodium for a therapeutic dosing period. Also provided is a method for preventing or treating thrombosis, such as thrombotic episodes, in a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater by treating that patient with enoxaparin.
[004] As used herein, "enoxaparin sodium" refers to the low molecular weight heparin (LMWH) approved by the U.S. Food and Drug Administration (FDA), or any other regulatory agency outside of the United States, as Lovenox® (enoxaparin sodium injection), Clexane® or Klexane®, and any LMWH approved by the FDA, or any other regulatory agency outside of the United States, pursuant to an application citing Lovenox® (enoxaparin sodium injection), Clexane® or Klexane® as the listed drug. Enoxaparin sodium is available from sanofi-aventis and sold in the United States in the form of enoxaparin sodium injection, under the trademark Lovenox® (Clexane® in some other countries). In general, enoxaparin sodium is obtained by alkaline degradation of heparin benzyl ester derived from porcine intestinal mucosa. Its structure is characterized, for example, by a 2-0-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-0-disulfo-D-glucosamine at the reducing end of the chain. The average molecular weight is about 4500 daltons. The molecular weight distribution is:
<2000 daltons < 20%
2000 to 8000 daltons > 68%
>8000 daltons < 18%
[005] Enoxaparin sodium injection is a sterile aqueous solution containing enoxaparin sodium. Enoxaparin sodium injection is available from sanofi-aventis at 100 mg/ml in prefilled syringes (30 mg/0.3 mL pre-filled syringes, 40 mg/0.4 mL pre- filled syringes, 60 mg/0.6 mL pre-filled syringes, 80 mg/0.8 mL pre-filled syringes, and 100 mg/1.0 mL pre-filled syringes), graduated prefilled syringes, multiple-dose vials (300 mg/3.0 mL multi-dose vials), and ampoules (30 mg/0.3 mL). Enoxaparin sodium injection 100 mg/mL concentration contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL water for injection. Enoxaparin sodium injection is also available from sanofi-aventis at 150 mg/ml in graduated prefilled syringes (90 mg/0.6 mL pre-filled syringes, 120 mg/0.8 mL prefilled syringes, and 150 mg/1.0 mL pre-filled syringes). Enoxaparin sodium injection 150 mg/mL concentration contains 15 mg enoxaparin sodium (approximate anti- Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 ml_ water for injection.
[006] The enoxapahn sodium injection prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection. There are also multiple-dose vials and those contain 15 mg/1.0 ml_ benzyl alcohol as a preservative. The pH of the injection is 5.5 to 7.5. Enoxaparin sodium injection may also be administered in an arterial line for a hemodialysis indication.
[007] As used herein, reference to administration of enoxaparin sodium once daily means, for example, administration every twenty-four hours plus or minus four hours.
[008] The term "prevent," "preventing" and "prevention" refers to the administration of therapy an individual who may ultimately manifest at least one symptom of a disease or condition (e.g., thrombosis) but who has not yet done so, to reduce the chance that the individual will develop the symptom of a disease or condition over a given period of time. Such a reduction may be reflected, for example, in a delayed onset of the at least one symptom of a disease or condition in the patient.
[009] As used herein, the term "treat," "treating" or "treatment" refers to the administration of therapy to an individual who already manifests at least one symptom of a disease or condition {e.g., thrombosis), or who has previously manifested at least one symptom of a disease or condition.
[010] "Body weight" refers to the weight of a patient that is determined by actual weighing or by estimation prior to administration of enoxaparin sodium. In the event that the body weight of a patient is estimated prior to administration of the first dose of enoxaparin sodium, the body weight of the patient may be subsequently determined by actual weighing before any subsequent dose of enoxaparin, and the amount of enoxaparin administered to the patient with the next subsequent dose adjusted accordingly.
[011] "Kg" refers to body weight of the patient in kilograms.
[012] As used herein, "stroke" refers to the new onset of focal or global neurological deficit caused by ischemia or hemorrhage within or around the brain and lasting for more than 24 hours. Intracranial hemorrhage may be diagnosed by appropriate brain imaging, including, for example, a CT or MRI that shows the presence of an acute blood mass. Ischemic or bland infarction may be diagnosed, for example, by appropriate imaging which shows the presence of one or more of the following: hypodensity, edema, midline shift or ventricular effacement without evidence of hemorrhage. Hemorrhagic conversion of an ischemic infarction may be diagnosed by appropriate imaging that shows an ischemic infarction with localized petechial or confluent bleeding into necrotic tissue.
[013] As used herein, "acute ischemic stroke" refers to strokes caused by thrombosis or embolism.
[014] As used herein, "NIH Stroke Scale" refers to National Institutes of Health Stroke Scale (NIHSS), used to measure the severity of neurological dysfunction at the time of a stroke. The Stroke Scale typically is measured within 1 hour of an MRI or CT scan. A score greater than 25 indicates very severe neurological impairment; a score between 15 and 25 indicates severe impairment, while a score between 5 and 15 mild to moderately severe impairment, and a score less than 5 mild impairment.
[015] As used herein, "therapeutic dosing period" refers to the period of time beginning with the administration of a first dose of enoxapahn sodium and ending with the administration of the last dose of enoxaparin sodium on a continuing basis. For example, if enoxaparin sodium is administered approximately every twenty-four hours for a total of nine doses, the therapeutic dosing period is approximately 9 days (or approximately 216 hours), the time between the first dose and the ninth.
[016] Provided is a method for treating a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater comprising administering to said patient at least one dose of 40 mg of enoxaparin sodium for a therapeutic dosing period. Also provided is a method for preventing or treating thrombosis, such as thrombotic episodes, in a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater by treating that patient with enoxaparin.
[017] In certain embodiments, prevention of thrombosis comprises prevention of subsequent thrombotic episodes. In certain embodiments, prevention of thrombosis comprises prevention of venous thrombosis. In certain embodiments, treatment of thrombosis comprises treatment of thrombotic episodes. In certain embodiments, treatment of thrombosis comprises treatment of venous thrombosis.
[018] Administration of enoxaparin sodium is, for example, by injection, and further for example, by subcutaneous injection.
[019] In certain embodiments, the therapeutic dosing period is, for example, at least 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, or 15 days. In certain embodiments, the therapeutic dosing period is about 10 days.
[020] The dosage of enoxaparin sodium administered during the therapeutic dosing period is, for example, at least 20 mg, from more than 20 mg to less than 60 mg, from 22 mg to 58 mg, from 25 mg to 55 mg, from 27 mg to 52 mg, from 30 mg to 50 mg, from 32 mg to 47 mg, from 35 mg to 45 mg, from 37 mg to 43 mg, about 40 mg, or 40 mg. In certain embodiments, about 40 mg (or 40 mg) of enoxaparin sodium is administered. Typically, the enoxaparin sodium will be administered once daily.
[021] In certain embodiments, the therapeutic dosing period is initiated with 48 hours of onset of stroke symptoms. In certain embodiments, the patient undergoes a CT or MRI scan prior to administration of enoxaparin sodium to, e.g., confirm the diagnosis of acute ischemic stroke.
[022] In certain embodiments, the patient is unable to walk without assistance due to motor impairment of one or both legs. In certain embodiments, the motor impairment has lasted for at least 24 hours prior to administration of enoxaparin sodium.
[023] The patient receiving enoxparin sodium typically will be 65 years of age or greater. In certain embodiments, the patient is, for example, at least 70 years of age, at least 75 years of age, at least 80 years of age, at least 85 years of age, or at least 90 years of age.
[024] In certain embodiments, the patient exhibits a NIH stroke score of, for example, at least 10, at least 11 , at least 12, at least 13, at least 14, or at least 15. In certain embodiments, the NIH stroke score is between about 5 and 15. In certain embodiments, the NIH stroke score is about 11.
[025] In certain embodiments, enoxaparin is administered in an amount sufficient to reduce the primary end-point of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment, as compared with an ACT-adjusted UFH regimen. DVT may be confirmed primarily by venography, or ultrasonography when venography was not practical. PE may be confirmed by VQ scan, CT scan, or angiography.
[026] In certain embodiments, administration of enoxapahn significantly reduced the incidence of the primary efficacy endpoint from by, for example, at least 30%, at least 35%, or at least 40%. In certain embodiments, the relative risk reduction was about 44%.
[027] In certain embodiments, the patient is administered at least one additional therapeutic agent. Such "co-therapy" (or "combination-therapy") may include the following examples: administration of each agent in a sequential manner in a regimen to provide beneficial effects of the drug combination; and/or co-administration of the aforementioned components in a substantially simultaneous manner (e.g., as in a single injection having a fixed ratio of these active agents or in multiple, separate injections for each agent, etc.).
[028] Thus, the methods described herein are not limited in the sequence of administration; the enoxaparin sodium may be administered either prior to, at the same time with or after administration of the other agent. In addition, enoxaparin sodium may be administered alone or in combination with other treatments, e.g., drug-eluting stent.
[029] In certain embodiments, the at least one additional therapeutic agent is chosen from thrombolytic agents, fibrinolytic agents, neuroprotective agents, and antiplatelet agents. In certain embodiments, the at least one additional therapeutic agent is a thrombolytic agent chosen from alteplase, anistreplase, reteplase, urokinase and streptokinase. In certain embodiments, the at least one additional therapeutic agent is a neuroprotective agent chosen from caspase inhibitors, glutamate antagonists, calcium antagonists, opiate antagonists, GABA-A agonists, calpain inhibitors, NMDA receptor antagonists, K.sup.÷ channel modulators, PDH kinase inhibitors, and antioxidants. In certain embodiments, the at least one additional therapeutic agent is an antiplatelet agent chosen from aspirin, clopidogrel, ticlopidine, abciximab, eptifibatide, tirofiban and dipyridamole.
[030] In certain embodiments, the at least one additional therapeutic agent is a GP llb/llla inhibitor. In certain embodiments, the GP llb/llla inhibitors include abciximab (marketed as ReoPro®), tirofiban (marketed as Aggrastat®), and eptifibatide (marketed as Integrelin®). In certain embodiments, the at least one additional therapeutic agent is tissue plasminogen activator. In certain embodiments, the at least one additional therapeutic agent is dipyridamole, such as extended release dipyridamole. I
[031] In certain embodiments, prevention of thrombosis comprises prevention of thrombotic episodes. In certain embodiments, treatment of thrombosis comprises treatment of thrombotic episodes.
[032] In providing enoxaparin sodium dosage regimens, the dosage regimen for administration of enoxaparin sodium is based on the particular indication. For each indication, methods are provided herein that include methods for preventing and/or treating acute ischemic stroke in a human patient.
[033] It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein are suitable and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples of the invention, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention.
EXAMPLE 1 : Prevail Study
[034] Patients with an acute ischemic stroke, confirmed by CT scan, and unable to walk without assistance due to motor impairment of the leg were enrolled in a prospective, open-label, parallel group, multicenter study. Patients were randomized within 48 hours of stroke symptoms to receive enoxaparin 40 mg SC o.d. or unfractionated heparin (UFH) 5000 IU SC q12h, for 10±4 days. The primary efficacy endpoint was the composite of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment. DVT was confirmed primarily by venography, or ultrasonography when venography was not practical. PE was confirmed by VQ scan, CT scan, or angiography. Primary safety endpoints included clinically significant intracranial bleeding and major extracranial bleeding.
[035] 1762 acute ischemic stroke patients from 15 countries were randomized. Baseline characteristics were similar between groups. The mean age was 66.0 ± 12.9 years and the mean NIH stroke score was 11.3. In the efficacy population (enoxaparin, n=666; UFH, n=669), the mean duration of prophylaxis was 10.5 days for both enoxaparin and UFH. Compared with UFH, enoxaparin significantly reduced the incidence of the primary efficacy endpoint from 18.1 % (121/669) to 10.2% (68/666), corresponding to a 44% relative risk reduction (p=0.0001 , adjusted for NIH stroke score stratification). The combined incidence of clinically significant intracranial and major extracranial bleeding was small and similar between groups (1.3% enoxaparin vs 0.7% UFH, p=0.2275).
[036] Among other things, the results of the Prevail Study indicate that enoxaparin 40 mg o.d. is significantly more effective than UFH q12h for preventing VTE in acute ischemic stroke patients, with similar safety.
EXAMPLE 2: Treatment of a Stroke Patient
[037] A patient who has suffered an acute ischemic stroke is identified. The patient is 66 years old and the NIH stroke score of the patient is determined to be 11.3. Enoxaparin is administered to the patient at a dose of 40 mg by subcutaneous injection once a day for ten days. During the ten days of treatment the patient does not suffer from any of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment. The patient also does not suffer clinically significant intracranial bleeding or major extracranial bleeding during the ten days of treatment.
[038] While the administration of enoxaparin sodium has been described in connection with certain embodiments, it is not intended to limit the invention to the particular forms set forth, but on the contrary, it is intended to cover such alternatives, modifications and equivalents as may be included within the spirit and scope of the invention as defined by the following claims.

Claims

What is claimed is:
1. A method for treating a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater comprising administering to said patient at least one dose of 40 mg of enoxaparin sodium for a therapeutic dosing period.
2. The method of claim 1 wherein enoxaparin sodium is administered by injection.
3. The method of claim 2 wherein enoxaparin sodium is administered by subcutaneous injection.
4. The method of claim 1 wherein the therapeutic dosing period is at least 6 days.
5. The method of claim 4 wherein the therapeutic dosing period is about 10 days.
6. The method of claim 1 wherein enoxaparin sodium is administered at a dosage of at least 20 mg once daily.
7. The method of claim 6 wherein enoxaparin sodium is administered at a dosage of about 40 mg once daily.
8. The method of claim 7 wherein enoxaparin sodium is administered at a dosage of 40 mg once daily.
9. The method of claim 1 wherein the therapeutic dosing period is initiated with 48 hours of onset of stroke symptoms.
10. The method of claim 1 wherein the patient undergoes a CT scan prior to administration of enoxaparin sodium.
11. The method of claim 1 wherein the patient is unable to walk without assistance due to motor impairment of one or both legs.
12. The method of claim 11 wherein the motor impairment has lasted for at least 24 hours prior to administration of enoxaparin sodium.
13. The method of claim 1 wherein enoxaparin sodum is administered in an amount sufficient to reduce the primary end-point of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment, as compared with an ACT-adjusted UFH regimen.
14. The method of claim 1 wherein the patient is administered at least one additional therapeutic agent.
15. The method of claim 14 wherein the at least one additional therapeutic agent is chosen from thrombolytic agents, fibrinolytic agents, neuroprotective agents, and antiplatelet agents.
16. A method for preventing or treating thrombosis comprising administering to a human patient 65 years of age or older with acute ischemic stroke or a mean NIH stroke score of 10 or greater at least one dose of 40 mg of enoxaparin sodium for a therapeutic dosing period.
17. The method of claim 16 wherein enoxaparin sodium is administered by injection.
18. The method of claim 17 wherein enoxaparin sodium is administered by subcutaneous injection.
19. The method of claim 18 wherein the therapeutic dosing period is at least 6 days.
20. The method of claim 19 wherein the therapeutic dosing period is about 10 days.
21. The method of claim 16 wherein enoxaparin sodium is administered at a dosage of at least 20 mg once daily.
22. The method of claim 21 wherein enoxaparin sodium is administered at a dosage of about 40 mg once daily.
23. The method of claim 22 wherein enoxaparin sodium is administered at a dosage of 40 mg once daily.
24. The method of claim 16 wherein the therapeutic dosing period is initiated within 48 hours of onset of stroke symptoms.
25. The method of claim 16 wherein the patient undergoes a CT scan prior to administration of enoxaparin sodium.
26. The method of claim 16 wherein the patient is unable to walk without assistance due to motor impairment of one or both legs.
27. The method of claim 26 wherein the motor impairment has lasted for at least 24 hours prior to administration of enoxaparin sodium.
28. The method of claim 16 wherein enoxaparin sodum is administered in an amount sufficient to reduce the primary end-point of symptomatic or asymptomatic deep-vein thrombosis (DVT), symptomatic pulmonary embolism (PE), or fatal PE, during treatment, as compared with an ACT-adjusted UFH regimen.
29. The method of claim 16 wherein the patient is administered at least one additional therapeutic agent.
0. The method of claim 29 wherein the at least one additional therapeutic agent is chosen from thrombolytic agents, fibrinolytic agents, neuroprotective agents, and antiplatelet agents.
PCT/US2007/082788 2006-10-30 2007-10-29 Use of enoxaparin sodium for treating patients with acute ischemic stroke WO2008055092A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85513706P 2006-10-30 2006-10-30
US60/855,137 2006-10-30

Publications (2)

Publication Number Publication Date
WO2008055092A2 true WO2008055092A2 (en) 2008-05-08
WO2008055092A3 WO2008055092A3 (en) 2008-07-03

Family

ID=39315336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/082788 WO2008055092A2 (en) 2006-10-30 2007-10-29 Use of enoxaparin sodium for treating patients with acute ischemic stroke

Country Status (4)

Country Link
AR (1) AR063530A1 (en)
CL (1) CL2007003121A1 (en)
TW (1) TW200835509A (en)
WO (1) WO2008055092A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017810A1 (en) * 2009-08-14 2011-02-17 Kardiatech, Inc. Combination therapy to treat vascular disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803522B1 (en) * 2000-01-06 2004-01-02 Aventis Pharma Sa NEW THERAPEUTIC APPLICATION OF ENOXAPARIN

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017810A1 (en) * 2009-08-14 2011-02-17 Kardiatech, Inc. Combination therapy to treat vascular disorders

Also Published As

Publication number Publication date
WO2008055092A3 (en) 2008-07-03
CL2007003121A1 (en) 2008-05-16
TW200835509A (en) 2008-09-01
AR063530A1 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
Clagett et al. Prevention of venous thromboembolism
RU2508124C2 (en) Using hyaluronidase for preventing or treating arterial hypertension or cardiac failure
Goldberg et al. Gangrene of the Upper Extremity Following Intra-arterial Injection of Drugs.
Howard Dalteparin: a low-molecular-weight heparin
US20220073888A1 (en) Combination treatment
US6258798B1 (en) Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
WO2008055092A2 (en) Use of enoxaparin sodium for treating patients with acute ischemic stroke
TW200927151A (en) Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof
US20120070471A1 (en) Administration of enoxoparin sodium to patients 75 years and older with st-segment elevation myocardial infarction
US20070191304A1 (en) Methods for performing percutaneous coronary intervention
CN104284667A (en) Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
Breddin Reviparin sodium–a new low molecular weight heparin
US20250195549A1 (en) New use
Wellington et al. Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism
Chew Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures
WO2025133022A1 (en) Fractalkine receptor antagonists for use in the prevention of thrombus formation and/or growth
Betz et al. Necrosis of the leg after intraarterial drug injection
US20130101524A1 (en) Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
Sudlow et al. Randomized trials of antiplatelet therapy
Hamaad et al. The METHRO trials
EP2484366A1 (en) Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
PL207144B1 (en) Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
JP2013529620A (en) Semlopaline to prevent lethal and / or morbidity in patients undergoing major orthopedic surgery
Hammond et al. Drugs for Medical Concerns in Traumaticbrain Injury
Sassout et al. Anticoagulation and

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868603

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07868603

Country of ref document: EP

Kind code of ref document: A2